Peanut Oral Immunotherapy: Is the Second Year the Charm?

[...]21% of actively treated participants in PALISADE discontinued treatment, over half due to adverse events. [...]although the numbers are small, it appears that the rate of systemic allergic reactions in the second year of OIT remains far higher than that of patients practicing avoidance alone. [...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The journal of allergy and clinical immunology in practice (Cambridge, MA) MA), 2021-05, Vol.9 (5), p.1890-1891
Hauptverfasser:	Dunlop, Joan H., Wood, Robert A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Allergens Drug dosages FDA approval Food allergies Hypersensitivity Immunotherapy Patients Quality of life
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!